Medicinal Chemistry Case History

Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate

M. A. Phillips, P. K. Rathod, T. Rueckle, D. Matthews, J. N. Burrows, S. A. Charman

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Half of the globe remains at risk for malaria, yet drug resistance threatens current treatments. DSM265 was discovered through a target-based screen and subsequent structure-guided lead optimization, as a novel triazolopyrimidine-based inhibitor of Plasmodium dihydroorotate dehydrogenase (DHODH). DSM265 is the first antimalarial targeting DHODH and, due to its novel mechanism, is expected to function against Plasmodium species resistant to current chemotherapies. Key DSM265 characteristics include blood- and liver-stage activity, parasite selectivity, and a long human half-life, supporting its development as either a single dose treatment or once weekly prophylactic, in combination with a suitable partner to help prevent resistance.

Original languageEnglish (US)
Title of host publicationCase Histories in Recent Drug Discovery
PublisherElsevier Inc.
Pages544-557
Number of pages14
Volume8-8
ISBN (Electronic)9780128032008
ISBN (Print)9780128032015
DOIs
StatePublished - Jun 3 2017

Fingerprint

Antimalarials
Oxidoreductases
Chemotherapy
Liver
Blood
Pharmaceutical Preparations
Pharmaceutical Chemistry
dihydroorotate dehydrogenase
Parasites
Lead

Keywords

  • Artemisinin.
  • DHODH.
  • Dihydroorotate dehydrogenase.
  • DSM265.
  • Malaria.
  • Plasmodium.
  • Pyrimidine.
  • Triazolopyrimidine

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Phillips, M. A., Rathod, P. K., Rueckle, T., Matthews, D., Burrows, J. N., & Charman, S. A. (2017). Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate. In Case Histories in Recent Drug Discovery (Vol. 8-8, pp. 544-557). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-409547-2.12470-9

Medicinal Chemistry Case History : Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate. / Phillips, M. A.; Rathod, P. K.; Rueckle, T.; Matthews, D.; Burrows, J. N.; Charman, S. A.

Case Histories in Recent Drug Discovery. Vol. 8-8 Elsevier Inc., 2017. p. 544-557.

Research output: Chapter in Book/Report/Conference proceedingChapter

Phillips, MA, Rathod, PK, Rueckle, T, Matthews, D, Burrows, JN & Charman, SA 2017, Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate. in Case Histories in Recent Drug Discovery. vol. 8-8, Elsevier Inc., pp. 544-557. https://doi.org/10.1016/B978-0-12-409547-2.12470-9
Phillips MA, Rathod PK, Rueckle T, Matthews D, Burrows JN, Charman SA. Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate. In Case Histories in Recent Drug Discovery. Vol. 8-8. Elsevier Inc. 2017. p. 544-557 https://doi.org/10.1016/B978-0-12-409547-2.12470-9
Phillips, M. A. ; Rathod, P. K. ; Rueckle, T. ; Matthews, D. ; Burrows, J. N. ; Charman, S. A. / Medicinal Chemistry Case History : Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate. Case Histories in Recent Drug Discovery. Vol. 8-8 Elsevier Inc., 2017. pp. 544-557
@inbook{eb247b1d98f543939b1dbef0b232d0ad,
title = "Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate",
abstract = "Half of the globe remains at risk for malaria, yet drug resistance threatens current treatments. DSM265 was discovered through a target-based screen and subsequent structure-guided lead optimization, as a novel triazolopyrimidine-based inhibitor of Plasmodium dihydroorotate dehydrogenase (DHODH). DSM265 is the first antimalarial targeting DHODH and, due to its novel mechanism, is expected to function against Plasmodium species resistant to current chemotherapies. Key DSM265 characteristics include blood- and liver-stage activity, parasite selectivity, and a long human half-life, supporting its development as either a single dose treatment or once weekly prophylactic, in combination with a suitable partner to help prevent resistance.",
keywords = "Artemisinin., DHODH., Dihydroorotate dehydrogenase., DSM265., Malaria., Plasmodium., Pyrimidine., Triazolopyrimidine",
author = "Phillips, {M. A.} and Rathod, {P. K.} and T. Rueckle and D. Matthews and Burrows, {J. N.} and Charman, {S. A.}",
year = "2017",
month = "6",
day = "3",
doi = "10.1016/B978-0-12-409547-2.12470-9",
language = "English (US)",
isbn = "9780128032015",
volume = "8-8",
pages = "544--557",
booktitle = "Case Histories in Recent Drug Discovery",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Medicinal Chemistry Case History

T2 - Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate

AU - Phillips, M. A.

AU - Rathod, P. K.

AU - Rueckle, T.

AU - Matthews, D.

AU - Burrows, J. N.

AU - Charman, S. A.

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Half of the globe remains at risk for malaria, yet drug resistance threatens current treatments. DSM265 was discovered through a target-based screen and subsequent structure-guided lead optimization, as a novel triazolopyrimidine-based inhibitor of Plasmodium dihydroorotate dehydrogenase (DHODH). DSM265 is the first antimalarial targeting DHODH and, due to its novel mechanism, is expected to function against Plasmodium species resistant to current chemotherapies. Key DSM265 characteristics include blood- and liver-stage activity, parasite selectivity, and a long human half-life, supporting its development as either a single dose treatment or once weekly prophylactic, in combination with a suitable partner to help prevent resistance.

AB - Half of the globe remains at risk for malaria, yet drug resistance threatens current treatments. DSM265 was discovered through a target-based screen and subsequent structure-guided lead optimization, as a novel triazolopyrimidine-based inhibitor of Plasmodium dihydroorotate dehydrogenase (DHODH). DSM265 is the first antimalarial targeting DHODH and, due to its novel mechanism, is expected to function against Plasmodium species resistant to current chemotherapies. Key DSM265 characteristics include blood- and liver-stage activity, parasite selectivity, and a long human half-life, supporting its development as either a single dose treatment or once weekly prophylactic, in combination with a suitable partner to help prevent resistance.

KW - Artemisinin.

KW - DHODH.

KW - Dihydroorotate dehydrogenase.

KW - DSM265.

KW - Malaria.

KW - Plasmodium.

KW - Pyrimidine.

KW - Triazolopyrimidine

UR - http://www.scopus.com/inward/record.url?scp=85040428304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040428304&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-409547-2.12470-9

DO - 10.1016/B978-0-12-409547-2.12470-9

M3 - Chapter

SN - 9780128032015

VL - 8-8

SP - 544

EP - 557

BT - Case Histories in Recent Drug Discovery

PB - Elsevier Inc.

ER -